GlassScriptPhysician profile
Joseph H Antin
NPI 1861469249
$98,213.54
in general payments reported to CMS, 2019-2025
21 companies · $14K in 2025
The $14K reported for 2025 was more than what 84% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,860 · 2021: $16K · 2022: $17K · 2023: $16K · 2024: $18K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Food and Beverage: $1,707 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500 · Travel and Lodging: $351 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,425.00 |
| Food and Beverage | $1,707.20 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
| Travel and Lodging | $351.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $38,100.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $10,309.92 | 2019-2022 | |
| Csl Behring | $9,600.00 | 2019-2025 | Zemaira |
| Pharmacosmos Therapeutics INC. | $7,600.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $7,529.19 | 2022-2023 | Empaveli, Empaveli |
| Alexion Pharmaceuticals, INC. | $5,271.15 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $5,245.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $3,700.00 | 2023-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $3,425.00 | 2022-2024 | |
| Medexus Pharma, INC. | $2,040.00 | 2024 | |
| National Marrow Donor Program | $1,554.13 | 2022-2025 | |
| Zoll Medical Corporation | $700.00 | 2022-2024 | Defibrillator |
| Celgene Corporation | $662.18 | 2023 | |
| Gamida Cell INC. | $500.00 | 2025 | Omisirge |
| Tersera Therapeutics LLC | $383.00 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $375.00 | 2024 | |
| Recordati_rare_diseases_inc. | $325.00 | 2024 | |
| Biogen, INC. | $310.00 | 2020 | |
| Eurofins Viracor, LLC | $283.13 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $150.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Antin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.